astragaloside a has been researched along with Cardiovascular Stroke in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, DD; Jin, G; Liu, X; Luan, X; Sun, Q; Tian, S; Wan, J; Wang, P; Wu, C; Yang, Y; Ye, LL; Zang, Y; Zhan, X; Zhang, W; Zhang, Z | 1 |
| Liu, L; Liu, Y; Ren, YK; Sui, YB; Zhang, KK | 1 |
| He, RH; Liu, XD; Ma, FZ; Ma, Q; Wang, J; Zhang, B | 1 |
| Gao, G; Liu, PP; Shi, H; Song, R; Wang, L; Wang, SS; Yin, G; Zhou, P; Zou, YY | 1 |
| Chang, H; Gong, L; Guo, G; Shi, J; Xu, H; Zhang, J | 1 |
| Liu, F; Liu, L; Sui, YB; Wang, Y; Zhang, YQ | 1 |
| Chen, D; Chen, J; Chen, X; Cheng, S; Feng, Q; Shen, L; Sun, W; Yang, L; Yu, P; Zhang, H; Zhang, X | 1 |
| Cao, Y; Chen, J; Chen, X; Hu, X; Li, X; Liu, H; Lu, S; Nie, J; Wu, X; Yang, Z; Zhao, X; Zhu, J | 1 |
| Jiang, W; Wang, HD; Yu, JM; Zhang, XB; Zhang, YN | 1 |
| Bi, S; Han, D; Li, Y; Wang, C; Yang, X; Zhang, D; Zhang, Y | 1 |
10 other study(ies) available for astragaloside a and Cardiovascular Stroke
| Article | Year |
|---|---|
Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456.
Topics: Animals; Cardiomegaly; Heart Failure; Humans; Mice; Myocardial Infarction; Myocytes, Cardiac | 2023 |
The role of Nrf2 in astragaloside IV-mediated antioxidative protection on heart failure.
Topics: Animals; Antioxidants; Cardiotonic Agents; Cell Line; Echocardiography; Heart Failure; Heme Oxygenase-1; Male; Myocardial Infarction; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Stroke Volume; Survival Analysis; Transcriptional Activation; Triterpenes | 2020 |
[Astragaloside Ⅳ's Therapeutic Effect on Myocardial Infarction via Affecting Autophagy and the Mechanism Study].
Topics: Animals; Apoptosis; Autophagy; Myocardial Infarction; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Saponins; Signal Transduction; Triterpenes | 2021 |
Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway.
Topics: Animals; Molecular Docking Simulation; Myeloid Differentiation Factor 88; Myocardial Infarction; NF-kappa B; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Toll-Like Receptor 4; Triterpenes | 2021 |
Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a.
Topics: Animals; Antagomirs; Apoptosis; Blood Pressure; Cell Hypoxia; Cell Line; Down-Regulation; Male; MicroRNAs; Mitogen-Activated Protein Kinases; Myocardial Infarction; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Protective Agents; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Triterpenes | 2018 |
Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway.
Topics: Angiogenesis Inducing Agents; Animals; Coronary Vessels; Disease Models, Animal; Heart Failure; Human Umbilical Vein Endothelial Cells; Humans; Janus Kinases; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardium; Platelet Endothelial Cell Adhesion Molecule-1; Random Allocation; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; STAT3 Transcription Factor; Triterpenes; Weight Gain | 2019 |
Astragaloside IV exerts angiogenesis and cardioprotection after myocardial infarction via regulating PTEN/PI3K/Akt signaling pathway.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Cardiotonic Agents; Cell Line, Tumor; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Male; Myocardial Infarction; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Triterpenes; Vascular Endothelial Growth Factor A | 2019 |
Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Drug Evaluation, Preclinical; Gene Deletion; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Monomeric GTP-Binding Proteins; Multiprotein Complexes; Myocardial Infarction; Myocytes, Cardiac; Neuropeptides; Ras Homolog Enriched in Brain Protein; Saponins; Signal Transduction; TOR Serine-Threonine Kinases; Triterpenes; Ventricular Remodeling | 2013 |
Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction.
Topics: Angiogenesis Inducing Agents; Animals; Coronary Vessels; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblast Growth Factor 2; Gene Expression; Male; Microvessels; Myocardial Infarction; Myocardium; Neovascularization, Physiologic; Rats, Wistar; Saponins; Triterpenes; Vascular Endothelial Growth Factor A | 2015 |
Tetramethylpyrazine and Astragaloside IV Synergistically Ameliorate Left Ventricular Remodeling and Preserve Cardiac Function in a Rat Myocardial Infarction Model.
Topics: Animals; Drug Synergism; Drug Therapy, Combination; Drugs, Chinese Herbal; Myocardial Infarction; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley; Saponins; Triterpenes; Vasodilator Agents; Ventricular Function, Left; Ventricular Remodeling | 2017 |